A Percutaneous Coronary Intervention-Thrombolytic Predictive Instrument to Assist Choosing Between Immediate Thrombolytic Therapy Versus Delayed Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction

American Journal of Cardiology

Volumn 101, Issue 6, 2008, Pages 790-795

  Kent, David M ^a   Ruthazer, Robin ^a   Griffith, John L ^a   Beshansky, Joni R ^a   Concannon, Thomas W ^a   Aversano, Thomas ^d   Grines, Cindy L ^b   Zalenski, Robert J ^c   Selker, Harry P ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACCURACY; ACUTE HEART INFARCTION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOT LYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; ST SEGMENT ELEVATION;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; DECISION MAKING; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; MALE; MARYLAND; MASSACHUSETTS; MIDDLE AGED; MODELS, THEORETICAL; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 40049089765     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.10.050     Document Type: Article

References (21)

1. Grines C., Patel A., Jijlstra F., Weaver W.D., Granger C., Simes R.J., and PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six month follow up and analysis of individual patient data from randomized trials. Am Heart J 145 (2003) 47-57
2. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
3. Kent D.M., Schmid C.H., Lau J., and Selker H.P. Is primary angioplasty for some as good as primary angioplasty for all? Modeling across trials and individual patients. J Gen Intern Med 17 (2002) 887-894
4. Thune J.J., Hoefsten D.E., Lindholm M.G., Mortensen L.S., Andersen H.R., Nielsen T.T., Kober L., Kelbaek H., and Danish Multicenter Randomized Study on Fibrinolytic Therapy Versus Acute Coronary Angioplasty in Acute Myocardial Infarction (DANAMI)-2 Investigators. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circulation 112 (2005) 2017-2021
5. Kent D.M., Ruthazer R., Griffith J.L., Beshansky J.R., Grines C.L., Aversano T., Concanon T.W., Zalenski R.J., and Selker H.P. Comparison of mortality benefit of immediate thrombolytic therapy versus delayed primary angioplasty. Am J Cardiol 99 (2007) 1384-1388
6. Kent D.M., Lau J., and Selker H.P. Balancing the benefits of primary angioplasty against the benefits of thrombolytic therapy for acute myocardial infarction: the importance of timing. Eff Clin Pract 4 (2001) 214-220
7. Nallomothu B.K., and Bates E.R. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol 92 (2003) 824-826
8. Selker H.P., Griffith J.L., Beshansky J.R., Schmid C.H., Califf R.M., D'Agostino R.B., Laks M.M., Lee K.L., Maynard C., Selvester R.H., Wagner G.S., and Weaver W.D. Patient-specific predictions of outcomes in myocardial infarction for real time emergency use: a thrombolytic predictive instrument. Ann Intern Med 127 (1997) 538-548
9. Selker H.P., Beshansky J.R., and Griffith J.L. TPI Trial Investigators. Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction. A multicenter, randomized, controlled, clinical effectiveness trial. Ann Intern Med 137 (2002) 87-95
10. Aversano T., Aversano L.T., Passamani E., Knatterud G.L., Terrin M.L., Williams D.O., Forman S.A., Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT), and Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT). Thrombolytic therapy vs. primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 287 (2002) 1943-1951
11. Rothwell P.M., and Warlow C.P. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modeling study. European Carotid Surgery Trialists' Collaborative Group. Lancet 353 (1999) 2105-2110
12. Rothwell P.M., Mehta Z., Howard S.C., Gutnikov S.A., and Warlow C.P. Treating individuals 3: from subgroups to individuals: general principles and the example of carotid endarterectomy. Lancet 365 (2005) 256-265
13. Kent D.M., Hayward R.A., Griffith J.L., Vijan S., Beshansky J.R., Califf R.M., and Selker H.P. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 113 (2002) 104-111
14. Hayward R.A., Kent D.M., Vijan S., and Hofer T.P. Reporting clinical trial results to inform providers, payers, and consumers. Health Affairs 24 (2005) 1571-1581
15. Hayward R.A., Kent D.M., Vijan S., and Hofer T.P. Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis. BMC Med Res Methodol 6 (2006) 18
16. Kent D.M., and Hayward R.A. Limitations of applying results of clinical trials to individual patients: the need for risk stratification. JAMA 298 (2007) 1209-1212
17. Hudson M.P., Grange C.B., Topol E.J., Pieper K.S., Armstrong P.W., Barbash G.I., Guerci A.D., Vahanian A., Califf R.M., and Ohman E.M. Early reinfarction after fibrinolysis: Experience from the Global Utilization of Streptokinase and Tissue Plasminogen Activator (alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) trials. Circulation 104 (2001) 1229-1235
18. De Luca G., Suryapranata H., Stone G.W., Antoniucci D., Tcheng J.E., Neumann F.J., Van de Werf F., Antman E.M., and Topol E.J. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
19. Nordmann A.J., Bucher H., Hengstler P., Harr T., and Young J. Primary stenting versus primary balloon angioplasty for treating acute myocardial infarction. Cochrane Database Syst Rev 2 (2005) CD005313
20. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., Claeys M.J., Cools F., Hill K.A., Skene A.M., McCabe C.H., Braunwald E., and CLARITY TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
21. Chen Z.M., Jiang L.X., Chen Y.P., Xie J.X., Pan H.C., Peto R., Collins R., Liu L.S., and COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621